Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2025-12-09 am EST			5-day change	1st Jan Change
83.23 ^EUR	-0.44%		-3.39%	-11.21%

Dec. 09	Guggenheim Downgrades Sanofi to Neutral From Buy	MT
Dec. 09	US FDA launches fresh safety scrutiny of approved RSV therapies for infants	RE

SANOFI : UBS maintains a Buy rating

Published on 07/09/2024 at 03:57 am EDT - Modified on 07/09/2024 at 04:43 am EDT

MarketScreener with dpa-AFX Analyser

Sanofi

-0.44%

Already positive, the research from UBS and its analyst Jo Walton still consider the stock as a Buy opportunity. The target price is unchanged at EUR 110.

Latest news about Sanofi

Dec. 09	Guggenheim Downgrades Sanofi to Neutral From Buy	MT
Dec. 09	US FDA launches fresh safety scrutiny of approved RSV therapies for infants	RE
Dec. 09	U.S. FDA officials inform Merck, Sanofi and AstraZeneca RSV antibody therapies would receive fresh safety scrutiny - sources familiar with the situation	RE
Dec. 08	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
Dec. 08	Sanofi warns of Insulin Lispro pen shortage says EMA	RE
Dec. 08	European Equities Traded in the US as ADRs Little Changed in Monday Trading	MT
Dec. 08	SANOFI : JP Morgan is Neutral	ZD
Dec. 05	SANOFI : Buy rating from Bernstein	ZD
Dec. 05	Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns	RE
Dec. 05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
Dec. 05	Kennedy's advisers scrap hepatitis B vaccine guidance for most children in major policy shift	RE
Dec. 04	Sanofi completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.	CI
Dec. 04	Sanofi Completes Vicebio Acquisition to Add Respiratory Vaccine Candidate	MT
Dec. 04	Sanofi Closes on UK Biotechnology Company Vicebio	MT
Dec. 04	Kennedy advisers delay vote to drop hepatitis B vaccine recommendation, a major policy shift	RE
Dec. 04	Sanofi Completes Acquisition of Vicebio
Dec. 04	Sanofi completes acquisition of Vicebio	RE
Dec. 04	LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-Driven Antibody Optimisation Programs	CI
Dec. 03	Sanofi Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03:15 PM
Dec. 03	Sanofi Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 11:30 AM
Dec. 02	Ovid Therapeutics Inc. Appoints Petra Kaufmann as Chief Medical Officer	CI
Dec. 01	Regeneron Pharmaceuticals, Inc. and Tessera Therapeutics, Inc. to Jointly Develop Tsra-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency	CI
Dec. 01	Tyra Biosciences, Inc. Appoints Heather Faulds as Chief Regulatory Officer, Effective December 8, 2025	CI
Nov. 28	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gain 4% for Week	MT
Nov. 26	CG Oncology, Inc. Announces Board and Committee Changes	CI

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

Jan. 29 - Q4 2025 Earnings Release

More about the company